US-based pharmaceutical company Zogenix has extended its co-marketing partnership with Battelle, for the DosePro needle-free drug delivery system through 29 March 2014. The partnership is focused on advancing out-licensing opportunities ...
Zogenix has commenced first IND clinical trial for Relday in patients with chronic, stable schizophrenia or schizoaffective disorder. Relday is based on a combination of its DosePro needle-free, subcutaneous drug delivery system with a ...
Tags: Clinical Trial, DosePro needle-free drug, pharmacokinetic